source
- STAT+: At ASCO, positive data for Bristol in multiple myeloma and Pfizer in lung cancerYou’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual meeting. Sign up for email editions here. We’re ASCOmaxxing. Rest…STAT · 2mo ago↗ source
- At ASCO, Merck makes case for a ‘cornerstone’ cancer drugStudy results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.BioPharma Dive · 2mo ago↗ source
- Bristol Myers unveils data for one of its next-gen blood cancer drugsCalled mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.